Company intelligence / Profile preview
Virna Therapeutics
Boston, Massachusetts, United Statesvirnatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Virna Therapeutics is a privately held preclinical biotech developing neutralizing monoclonal antibodies and other antiviral modalities against SARS-CoV-2 and other RNA viruses; as of available public information, its candidates had not yet entered human clinical trials and no clinical results have been reported[2][3][4].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodySmall moleculeRNA therapyCRISPR-based therapyAntibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Toronto[3][4]Government of Canada (funding support)[2]Government of Italy (manufacturing and clinical development support)[2]Intonation Research Laboratories (exclusive development and marketing partner for South East Asia)[2]
Beyond the preview
Go deeper on Virna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virna Therapeutics.